General

Guideline Title


Bibliographic Source(s)


Guideline Status

This is the current release of the guideline.

This guideline updates previous versions:


This guideline meets NGC's 2013 (revised) inclusion criteria.

Recommendations

Major Recommendations

Definitions of the levels of the recommendations (A, B, C, U) and classification of the evidence (Class I-IV) are provided at the end of the "Major Recommendations" field.

Blepharospasm
Recommendations

OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) injections should be considered (Level B), and aboBoNT-A may be considered (Level C), as treatment options for blepharospasm.

Clinical Context

Botulinum neurotoxin (BoNT) is considered the first-line treatment of blepharospasm by most movement disorder specialists. All 3 type A toxins appear to have similar efficacy and can continue to be efficacious over long periods.

Cervical Dystonia (CD)

Recommendations

AbobotulinumtoxinA (aboBoNT-A) and rimabotulinumtoxinB (rimaBoNT-B) should be offered (Level A), and onaBoNT-A and incoBoNT-A should be considered (Level B), as options for the treatment of CD.

Clinical Context

BoNT is accepted as first-line treatment for CD. Although the evidence levels may differ across BoNT serotypes and brands, all formulations have regulatory approval and are commonly used. There is an extensive clinical history of onaBoNT-A and incoBoNT-A use, but the lack of additional Class I studies led to only a Level B recommendation. Comparative trials indicate similar efficacy for rimaBoNT-B and onaBoNT-A, and for aboBoNT-A and onaBoNT-A, in the treatment of CD.

Spasticity in Adults

Upper Extremity Spasticity

Recommendations

- For focal manifestations of adult spasticity involving the upper limb, aboBoNT-A, incoBoNT-A, and onaBoNT-A should be offered (Level A), and rimaBoNT-B should be considered (Level B), as treatment options.
- OnaBoNT-A should be considered as a treatment option before tizanidine (TZD) for treating adult upper extremity spasticity (Level B).
- Both high-volume, low-potency injections of onaBoNT-A and endplate targeting of onaBoNT-A into proximal upper extremity muscles should be considered to enhance tone reduction in spasticity (Level B).

Lower Extremity Spasticity

Recommendations

For focal manifestations of adult spasticity involving the lower limb that warrant treatment, onaBoNT-A and aboBoNT-A should be offered (Level A) as treatment options.

There is insufficient evidence to support or refute a benefit of incoBoNT-A or rimaBoNT-B for treatment of adult lower limb spasticity.

Clinical Context

Although BoNT can reduce increased tone in spasticity, the impact of BoNT injections on functional outcomes is mixed, suggesting that potential functional gains are highly patient-specific. Because of the lack of comparative trials, there is insufficient evidence to indicate that any one of the BoNT formulations is superior to the others.

Headache

Chronic Migraine (CM)

Recommendations

OnaBoNT-A should be offered as a treatment option to patients with CM to increase the number of headache-free days (Level A) and should be considered to reduce headache impact on health-related quality of life (QOL) (Level B).

Clinical Context

Although the reduction of headache days with onaBoNT-A was statistically superior to placebo in 2 Class I studies, the magnitude of the
difference is small (1.7 and 2.3).

Episodic Migraine (EM)

Recommendation

OnaBoNT-A should not be offered as a treatment for EM (Level A).

Definitions

Therapeutic Classification of Evidence Scheme

Class I

A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.

The following are also required:

a. Concealed allocation
b. Primary outcome(s) clearly defined
c. Exclusion/inclusion criteria clearly defined
d. Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias
e. For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*:
   1. The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority
   2. The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective)
   3. The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment
   4. The interpretation of the study results is based on a per-protocol analysis that accounts for dropouts or crossovers

Class II

A randomized, controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria a–e above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b–e above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.

Class III

All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.**

Class IV

Studies not meeting Class I, II, or III criteria, including consensus or expert opinion.

*Numbers 1–3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III.

**Objective outcome measurement: An outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).

Classification of Recommendations

A = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies).*
Clinical Algorithm(s)

None provided

Scope

Disease/Condition(s)
- Blepharospasm
- Cervical dystonia (CD)
- Adult spasticity
- Headache

Guideline Category

Assessment of Therapeutic Effectiveness

Treatment

Clinical Specialty

Neurology

Intended Users

Physicians

Guideline Objective(s)

To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity

Target Population

Patients with blepharospasm, cervical dystonia (CD), adult spasticity, and headache

Interventions and Practices Considered

Botulinum neurotoxin (BoNT), including
1. AbobotulinumtoxinA (aboBoNT-A)
2. IncobotulinumtoxinA (incoBoNT-A)
3. OnabotulinumtoxinA (onaBoNT-A)
4. RimabotulinumtoxinB (rimBoNT-B)

Major Outcomes Considered
- Headache-free days
- Range of motion
- Safety
- Quality of life (QOL)

Methodology

Methods Used to Collect/Select the Evidence

Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases

Description of Methods Used to Collect/Select the Evidence

The committee searched the EMBASE, Medline, and Science Citation Index databases to find relevant studies published from April 2007 (endpoint of the search performed for the prior guidelines) to August 2011. They updated the search in December 2014 and again in October 2015. The bibliographies of review articles also were searched to identify articles missed by the initial search strategy (see Appendix e-3 for complete search strategy). Additionally, because studies comparing different botulinum neurotoxin (BoNT) formulations in the treatment of cervical dystonia (CD) were not included in the 2008 guideline, they repeated the pre-2008 search to identify comparative trials.

To be eligible for inclusion, English-language articles had to compare outcomes between patients with blepharospasm, CD, adult spasticity, or headache receiving a preparation of BoNT that is commercially available in the United States with outcomes of a group of patients receiving an alternative therapy. Acceptable alternative therapies included placebo or another treatment—including a different form of BoNT or a different technique for administering BoNT. At least 20 patients must have been enrolled in each study. In general, only randomized, masked trials (RMTs) were considered. When RMTs were not available to assess long-term outcomes or safety concerns, evidence from nonrandomized trials was used.

Refer to Appendix e-3 in the supplement (see the "Availability of Companion Documents" field) for search terms.

The search identified 3,371 citations. A review of titles and abstracts identified 55 potentially relevant articles for blepharospasm, 100 for CD, 279 for spasticity, and 144 for headache. The committee reviewed the full text of these articles for meeting inclusion criteria.

Number of Source Documents

Twenty-three articles on blepharospasm, 23 on cervical dystonia (CD), 86 on spasticity, and 28 on headache met inclusion criteria. Table 2 in the original guideline document summarizes the conclusions from this review.

Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)
Rating Scheme for the Strength of the Evidence

Therapeutic Classification of Evidence Scheme

Class I
A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.

The following are also required:

a. Concealed allocation
b. Primary outcome(s) clearly defined
c. Exclusion/inclusion criteria clearly defined
d. Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias
e. For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*:
   1. The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority
   2. The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective)
   3. The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment
   4. The interpretation of the study results is based on a per-protocol analysis that accounts for dropouts or crossovers

Class II
A randomized, controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria a–e above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b–e above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.

Class III
All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.**

Class IV
Studies not meeting Class I, II, or III criteria, including consensus or expert opinion.

*Numbers 1–3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III.

**Objective outcome measurement: An outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).

Methods Used to Analyze the Evidence

Systematic Review with Evidence Tables

Description of the Methods Used to Analyze the Evidence

Each article was reviewed by at least 2 panelists who did not participate in or have a relevant conflict of interest with the reported trial. The panel classified each article for risk of bias (Class I, II, III, or IV) using the American Association of Neurology (AAN) classification scheme for therapeutic questions (see the "Rating Scheme for the Strength of the Evidence" field). Disagreements about article selection and classification were
resolved by consensus.

Methods Used to Formulate the Recommendations

Expert Consensus

Description of Methods Used to Formulate the Recommendations

The panel formulated recommendations on the basis of the conclusions; recommendations are tied directly to the evidence (see Appendix e-5 in the Data Supplement [see "Availability of Companion Documents"]). Table e-1 (see Data Supplement in the "Availability of Companion Documents") presents the conclusions and recommendations for efficacy of various botulinum neurotoxin (BoNT) formulations.

Unlike the approach taken in previous American Academy of Neurology (AAN) guidelines, where BoNT was evaluated for safety and efficacy as a single class, in this update the panel assessed each formulation separately for each indication. As a result, the level of support for efficacy in the conclusions and recommendations may be lower for the individual BoNT formulations than it would be had BoNT been considered as a class. The recommendations reflect the confidence in the level of evidence, but because studies of comparative efficacy are few, the recommendations should not be construed to indicate that one drug is superior to another.

Rating Scheme for the Strength of the Recommendations

Classification of Recommendations

A = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies).*

B = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)

C = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)

U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.

*In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome >5 and the lower limit of the confidence interval is >2).

Cost Analysis

The guideline developers reviewed published cost analyses.

Method of Guideline Validation

External Peer Review

Internal Peer Review

Description of Method of Guideline Validation

Drafts of the guideline have been reviewed by at least 3 American Academy of Neurology (AAN) committees, a network of neurologists, Neurology peer reviewers, and representatives from related fields.

The guideline was approved by the Guideline Development Subcommittee on November 16, 2013; by the Practice Committee on February 27, 2015; and by the AAN Institute Board of Directors on January 19, 2016.
Evidence Supporting the Recommendations

Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits

- Improved health-related quality of life (QOL)
- Reduced caregiver burden
- Improved limb muscle function

Potential Harms

- Commonly reported adverse events (AEs) with botulinum neurotoxin (BoNT) injections included periorbital hematoma (25%), ptosis (range of risk differences [RDs] 13%-54%), dry eyes (range of RDs 7.1%-13%), and blurred vision (RD 42%).
- In a placebo-controlled study, rhinitis and treatment-related dysphagia were more frequent with onabotulinumtoxinA (onaBoNT-A).

Qualifying Statements

Qualifying Statements

The regulatory approved indications for botulinum neurotoxin (BoNT) do not necessarily correspond to those in the evidence-based recommendations presented in the guideline.

Disclaimer

Clinical practice guidelines, practice advisories, systematic reviews, and other guidance published by the American Academy of Neurology (AAN) and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information: (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. The AAN provides this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

Implementation of the Guideline

Description of Implementation Strategy

An implementation strategy was not provided.

Implementation Tools
Institute of Medicine (IOM) National Healthcare Quality Report Categories

IOM Care Need
Getting Better
Living with Illness

IOM Domain
Effectiveness
Patient-centeredness
Safety

Identifying Information and Availability

Bibliographic Source(s)


Adaptation

Not applicable: The guideline was not adapted from another source.

Date Released

2016 May 10

Guideline Developer(s)

American Academy of Neurology - Medical Specialty Society
Source(s) of Funding

This guideline was developed with financial support from the American Academy of Neurology (AAN). Authors who serve as AAN subcommittee members or methodologists (E.J.A., G.S.G., M.J.A., D.G., S.P.) were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of manuscripts were reviewed.

Guideline Committee

Guideline Development Subcommittee of the American Academy of Neurology (AAN)

Composition of Group That Authored the Guideline

Guideline Authors: David M. Simpson, MD; Mark Hallett, MD; Eric J. Ashman, MD; Cynthia L. Comella, MD; Mark W. Green, MD; Gary S. Gronseth, MD; Melissa J. Armstrong, MD; David Gloss, MD; Sonja Potrebic, MD, PhD; Joseph Jankovic, MD; Barbara P. Karp, MD; Markus Naumann, MD; Yuen T. So, MD, PhD; Stuart A. Yablon, MD

2013–2015 Guideline Development Subcommittee (GDS) Members: Cynthia Harden, MD (Chair); Steven R. Messé, MD (Vice-Chair); Richard L. Barbano, MD, PhD; Jane Chan, MD; Diane Donley, MD; Terry File, MD; Jeffrey Fletcher, MD; Michael Haboubi, MD; John J. Halperin, MD; Cheryl Jaigobin, MD; Andres M. Kanner, MD; Jason Lazarou, MD; David Michelson, MD; Pushpa Namanyanswami, MD, MBBS; Maryam Oskoui, MD; Tamara Pringsheim, MD; Alexander Rae-Grant, MD; Kevin Sheth, MD; Kelly Sullivan, PhD; Theresa A. Zesiewicz, MD; Jonathan P. Hosey, MD (Ex-Officio); Stephen Ashwal, MD (Ex-Officio); Deborah Hirtz, MD (Ex-Officio); Jacqueline French, MD (Ex-Officio)

Financial Disclosures/Conflicts of Interest

Conflict of Interest

The American Academy of Neurology (AAN) is committed to producing independent, critical, and truthful clinical practice guidelines. Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this clinical practice guideline. To the extent possible, the AAN keeps separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN limits the participation of authors with substantial conflicts of interest. The AAN forbids commercial participation in, or funding of, guideline projects. The AAN Guideline Author Conflict of Interest Policy can be viewed at www.aan.com. For complete information on this process, access the 2004 AAN process manual.

Disclosure

D. Simpson has received research grants from and served as a consultant for Allergan Inc., Ipsen Ltd., Merz Pharmaceuticals, and Acorda Therapeutics. M. Hallett serves as a chair of the Neurotoxin Institute Advisory Council and has received research grants from Allergan Inc. and Merz Pharmaceuticals. E. Ashman served as a paid editor for Neurology® from 2011 to 2013. C. Comella has received research grants from and has served as a consultant for Allergan Inc., Ipsen Ltd., Merz Pharmaceuticals, and Revance Pharmaceuticals. M. Green and G. Gronseth report no disclosures relevant to the manuscript. M. Armstrong serves on the Level of Evidence Review Team for Neurology (not compensated financially) and serves as an evidence-based methodologist for the AAN. She has no conflicts of interest related to the topic of this guideline. D. Gloss and S. Potrebic report no disclosures relevant to the manuscript. J. Jankovic has received research grants from and served as a consultant for Allergan Inc., Ipsen Ltd., and Merz Pharmaceuticals. B. Karp has received a research grant from Allergan Inc. M. Naumann has served as a consultant for Allergan Inc. and Ipsen Ltd. Y. So reports no disclosures relevant to the manuscript. S. Yablon has served as a consultant for Allergan Inc., Ipsen Ltd., Medtronic Inc., and Merz Pharmaceuticals. Go to Neurology.org for full disclosures.

Guideline Endorser(s)

American Association of Neuromuscular and Electrodiagnostic Medicine - Medical Specialty Society

American Society of Plastic Surgeons - Medical Specialty Society
Guideline Status

This is the current release of the guideline.

This guideline updates previous versions:


This guideline meets NGC's 2013 (revised) inclusion criteria.

Guideline Availability

A list of American Academy of Neurology (AAN) guidelines, along with a link to this guideline, is available from the AAN Web site.

Availability of Companion Documents

The following are available:


Patient Resources

The following is available:
